Areas of interest (AOI) & competitive research grants
We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.
| Therapeutic Area and / or Compound | AOIs Posted on BMS.com | Pre-Concept Submission Period | |
| Start Date | End date | ||
| CV-Mavacamten -2024 RFP Cycle 2 | Jul 15, 2024 | Sept 02, 2024 | Sept 13, 2024 |
| Immunology – Sotyktu (Deucravacitinib) – Dermatology | Aug 26, 2024 | Sept 23, 2024 | Nov 14, 2024 |
| Immunology – Sotyktu (Deucravacitinib) - Rheumatology | Aug 26, 2024 | Sept 23, 2024 | Nov 26, 2024 |
CV-Mavacamten - 2024 RFP Cycle 2
Nonobstructive HCM disease progression and management
In Scope:
- Patient journey to diagnosis
- Symptom burden
- Practice patterns
Out of Scope:
- Off-label use of Camzyos
- Viz-AI algorithm
CAMZYOS impact on cardiac structure and function
In Scope:
- Association between indicators of remodeling and clinical outcomes.
- Impact on patients with earlier disease (less symptomatic, milder phenotype)
Out of Scope:
- Off-label (asymptomatic obstructive HCM; non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data. Myosin genotyping; re-analysis of clinical trial data
- Pediatric populations
- Viz-AI algorithm
- Repeat of BMS-led studies (Mava-LTE, sub-analysis of clinical data, CMR study)
CAMZYOS echo monitoring.
In Scope:
- Assess the benefits of innovative technologies to improve quality outcomes and enhance coordination of care, and health equity in patients on CAMZYOS
Out of Scope:
- Off-label (asymptomatic obstructive HCM; non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data. Myosin genotyping; re-analysis of clinical trial data
- Pediatric populations
- Viz-AI algorithm
Implementation of best practices
In Scope:
- Decision-making support to include patient-preference
- Approaches to Workflow optimization and co-management (quality-improvement studies)
- Approaches that incorporate technology to streamline HCM patient management
Out of Scope:
- Off-label (asymptomatic obstructive HCM; non-obstructive HCM, etc.); head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; re-analysis of clinical trial data. Myosin genotyping; re-analysis of clinical trial data.
- No Biomarker data
- Pediatric populations
- Viz-AI algorithm
- Non-research-focused concepts
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.
- If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here
- If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
- If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
- If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here